Safety Study of Specific Tumor Target Drug Plus Immune System Therapy in Patients With Kidney Cancer

The Methodist Hospital Research Institute (TMHRI)

Status and phase

Terminated

Phase 2

Conditions

Carcinoma, Renal Cell

Treatments

Drug: Interleukin-2

Drug: Bevacizumab

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT00440973

16117 (Other Identifier)

PAC IRB #03-0194-05

Details and patient eligibility

About

The purpose of this study is to determine if the combination of therapy to strengthen the immune system (Interleukin - 2) plus a specific tumor target therapy (Bevacizumab) can prolong the time between the start of treatment and disease progression, decrease tumor size, as well as determine if the combination therapy is safer and less toxic than the standard treatment for renal cell carcinoma.

Full description

The standard first-line treatment for patients with metastatic RCC is IL-2 at higher doses, but associated with higher frequency of toxicities. IL-2 given at lower doses have demonstrated similar results than higher doses but it requires further study. RCC is highly vascular and expresses high levels of VEGF. Bevacizumab is a monoclonal antibody directed against the Vascular Endothelial Growth Factor (VEGF) responsible for angiogenesis.

The study is designed to evaluate a response defined as time to progression, safety and toxicity in patients with metastatic renal cell carcinoma. Tissue correlation to evaluate the impact of vascular VEGF on clinical outcome will be retrospectively performed

Enrollment

6 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Pathological proof of clear cell carcinoma (or mixed tumors ≥ 75% clear cell component)
Evidence of measurable metastatic disease, no progression diseases or the patient's condition will not need radiotherapy in the next 4 weeks.
Previous definitive radiotherapy to 1 metastatic site is acceptable
At least 4 weeks have elapsed since radiation therapy
Patients must be free of serious co-morbidity and have a life expectancy of ≥24 weeks
Patients should have adequate physiologic reserves as evidence of adequate performance status, blood parameters, hepatic and kidney function, no evidence of active cardiac diseases and showing an acceptable function and adequate coagulation profile.

Exclusion criteria

History of central nervous System metastases
Known HIV positive
Recent history of brain's vascular disease within 6 months; patients requiring regular antianginal therapy (coronary disease) or insufficient circulation in lower extremities are not eligible
Active autoimmune disease
Patients who have had steroid therapy in the past three weeks
Patients taking concurrent anticancer drugs
Biphosphonates (Zometa) are not allowed, unless started 4 weeks prior to participation in the study
Female patients pregnant or breast-feeding
The patient has an unstable medical condition, such as uncontrolled Diabetes mellitus or Hypertension; active infections requiring systemic antibiotics, antivirals, or antifungal; clinical evidence of cardiac or pulmonary dysfunction including, uncontrolled arrhythmias, unstable coagulation disorders; or recent myocardial infarction (within 6 months)
Any condition including abnormal laboratory results, that in the opinion of the investigator places the patient at an unacceptable risk if he/she participate in the study
Prior malignancy (within the last 3 years), except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer or other cancer for which the patient has been - free for at least 3 years
Uncontrolled Blood pressure > 150/100
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 0, anticipation of need for major surgical procedure during the course of the study
Minor surgery 7 days before day 0
Serious, non healing wound, ulcer, or bone fracture; and,inability to accomplish the treatment